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Sleep disturbance is common in patients with Parkinson disease (PD), but it is often undetected due to
inadequate history taking and poor self-reporting. Impaired sleep can have a severe impact on health,
general well being, and quality of life. Sleep problems in PD have many potential causes, including the
direct effect of PD itself, adverse events of anti-Parkinsonian medications, daytime sleep disturbance, age
related causes, and other comorbidities. Patients with PD and their sleep partners should be asked about
sleep disturbances and other night-time symptoms. Treatment strategies rely on identifying causal
factors and need to be tailored to the individual and reviewed regularly.
Copyright  2012, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
Open access under CC BY-NC-ND license.LLC.1. Introduction
This article will review the epidemiology, pathophysiology, and
management of sleep disturbance in Parkinson disease (PD). We
identiﬁed references for this article by searching PubMed database
and Google Scholar up to 2011, with Medical Subject Headings
(MeSH) terms of “Parkinson disease,” “night-time symptoms,”
“sleep disorders,” “elderly,” and ”dopaminergic therapy.” Only
English-language literature was included in the search and infor-
mationwas also obtained from international proceedings published
in journals specializing in Parkinsonism and related disorders.
In his original monograph, James Parkinson evidently docu-
ments sleep-related disturbances associated with PD as: “His
attendants observed, that of late the trembling would sometimes
begin in his sleep, and increase until it awakened him: when he
always was in a state of agitation and alarm”.1 Sleep disturbance in
patients with PD may be caused by direct complications of the
disease, adverse events from PD medications, age-related alter-
ations in sleep patterns, associated comorbidities, neuropsychiatric
complications of PD, or a combination of the above.
In recent times, there has been increased interest in attempting
to better qualify and quantify sleep problems in PD. This has led tor the Elderly, Addenbrooke’s
ation Trust, Hills Road, Cam-
s.uk (D.R. Forsyth).
linical Gerontology & Geriatrics. Psome understanding and better management of nocturnal symp-
toms that plague patients with PD. The U.K. National Institute of
Clinical Health and Effectiveness (NICE) recognizes the nonmotor
symptoms (NMSs) and their management, which encompass sleep-
related problems in PD, as an unmet need.2e4
Sleep disturbances in PD are often poorly recognized, yet early
identiﬁcation and treatment to maintain or improve quality of
sleep can facilitate improvement in motor symptoms,5e8 improve
quality of life (QoL) for caregivers and patients, may delay institu-
tionalization, and may reduce healthcare costs.4
Furthermore, poor nocturnal sleep quality can lead to poor
daytime functioning and excessive daytime somnolence (EDS),
which may, in turn, be associated with increased cardiovascular
risk and cognitive impairment.9,10
Sleep disturbance is reported by around 25% of spouses of
patients with PD.11 Sleep disturbances in both patients with PD and
their sleep partners contribute to caregiver burden and correlate
with levels of depression in carers.12,132. Epidemiology
Estimates of the prevalence of sleep disturbance in PD range
from 25%e98%.5,14 Differences in methodology and selection bias
are thought to account for this wide variation. Sleep problems are
approximately twice as common in patients with PD (60%e64%) as
in age and sex matched controls (33%)6,7 and are also more prev-
alent than in those with other chronic conditions.15,16ublished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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may even predate the onset of PD. There is conﬂicting evidence as
to whether the degree of sleep disorder correlates with Hoehn and
Yahr staging of PD.14,16,17
The NMSQuest (a validated NMS questionnaire) study reported
that sleep problems such as restless legs syndrome (RLS), EDS, and
rapid eye movement sleep behavior disorder (REMSBD) are
signiﬁcantly more common in patients with PD compared with
controls.18
Smith and colleagues11 reported that 27% of male and 48%
female spouses of patients with PD experienced night-time
disturbances. The FAQT-study (prospective German cohort study
evaluating determinants of quality of life) investigators reported
a high prevalence of sleep disturbances in partners of patients with
PD associated with13:
 Higher Uniﬁed Parkinson’s Disease Rating Scale (UPDRS) motor
scores [odds ratio (OR) 2.8 per 10-point increase, p¼ 0.008]
 Poor sleep in the patient with PD (OR 4.0, p¼ 0.008)
 Male patients (OR 5.0, p¼ 0.008)
 Increasing care-giving frequency (OR 7.4 for daily caregiving
frequency, p¼ 0.004)
Neuropsychiatric symptoms such as depression, anxiety, apathy,
and cognitive impairment are common in PD and may impair
sleep.19e22 Sleep disorders are also more prevalent in patients with
PD who later develop cognitive impairment and may herald more
complex subtypes of PD.23
In advanced PD, motor symptoms of nocturnal “off” periods,
early morning akathisia, dystonia, freezing, and tremor can be very
troublesome. Nocturia is reported by up to 62% of patients with
PD18 and has been linked to impaired sleep in up to 70.4% of those
with idiopathic PD.24
3. Pathophysiology of sleep dysfunction in PD
The pathophysiology of sleep dysfunction in PD is multifactorial,
complex, and, as of yet, incompletely understood. Sleep dysfunc-
tion, like other nonmotor features of PD, is known to predate the
onset of motor dysfunction. REMSBD and depressionmight precede
the expression of motor features by more than a decade.2,25 This
has often led to misdiagnosis, inappropriate referrals, and delayed
treatment.26
3.1. Lewy body pathology and dopamine dysfunction
The progression of Lewy body pathology in PD closely correlates
with the occurrence of NMSs predating the motor dysfunction,27,28
suggesting that Lewy body deposition and neuronal dysfunction
commence in the olfactory bulb and lower medulla. Motor features
appear only when the substantia nigra pars compacta is affected by
loss of dopaminergic neurons. The axons from the key dopami-
nergic areas (substantia nigra pars compacta, ventral tegmental
area, and the hypothalamus) project extensively to form the four
main pathwaysdthe mesocortical, mesolimbic, nigrostriatal, and
tuberoinfundibular pathwaysdthat mediate NMS such as sleep,
cognition, and pain.21 11C-raclopride positron emission tomography
(PET) imaging in patients with PD has demonstrated dopamine
dysfunction in the hypothalamus.29
3.2. Degeneration in raphe nucleus and locus coeruleus
As sleep disturbance may precede motor dysfunction, it is
postulated that degeneration occurs in areas such as raphe nucleus
(serotonin) and locus coeruleus (noradrenaline) therebyconstituting the pre-clinical stages 1 and 2 of Braak’s pathological
staging of PD.27 These nuclei play a critical role in the sleep-wake
cycle and thalamocortical arousal, and their degeneration leads to
disruption of basic sleep architecture [both rapid eye movement
(REM) and noneREM], thereby manifesting as insomnia, para-
somnias and hallucinations.30,31
3.3. Inﬂuence of the pedunculopontine and retro-rubral nuclei on
REMSBD
The pedunculopontine nucleus and the retro-rubral nucleus
have been implicated in the pathogenesis of REMSBD due to their
strong inﬂuences on REM atonia and phasic generator circuitry.31
3.4. Destabilization of the ﬂip-ﬂop-switch regulation of sleep-wake
cycle
Saper32 proposed the ﬂip-ﬂop-switch pattern of regulation of
the sleep-wake cycle, describing that the brain could be either “off”
(asleep by activating the ventrolateral preoptic area, the sleep
promoter) or “on” (in quiet wakefulness with the activation of the
tuberomammillary nucleus, the wake-promoting area along with
locus coeruleus and the raphe nuclei). The suprachiasmatic nucleus
regulates the internal rhythm between the two switches. The
hypothalamic peptide that is virtually undetectable in narcolepsy;
hypocretin 1 (orexin) is thought to have a complex relationship in
the dopaminergic systems within the basal ganglia and may func-
tion as an external regulator of the ﬂip-ﬂop switch promoting
wakefulness.31,33 Destabilization of this switch and its regulators
occur in PD secondary to dopaminergic dysfunction and neuronal
degeneration, resulting in rapid transitions to sleep intruding
on wakefulness. The hypothesis of dopaminergic medications
reducing levels of hypocretin 1 and producing sleepiness could not
be conﬁrmed by cerebrospinal ﬂuid (CSF) analysis in three patients
with PD and EDS associated with dopamine agonist (DA) use.34
3.5. Age-related changes
In addition to these PD related changes, there are age-related
changes in sleep and circadian rhythm. Older people often sleep
for shorter periods of time at night and have more daytime naps
than their younger counterparts. Sleep architecture also alters with
ageing, with reduced Stages 3 and 4 of noneREM sleep. Around 40%
of older people experience some form of sleep disturbance and
these are more common in those with physical and psychological
problems.35
4. Causes
The main causes of nocturnal sleep problems and EDS are
nocturnal motor symptoms of PD, adverse effects of medications
used for PD, NMSs of PD (including neuropsychiatric symptoms,
sleep dysfunction, dysautonomia), other comorbidities, concomi-
tant medications, and age-related alterations in sleep patterns
(Tables 1 and 2).
4.1. Motor function/treatment related
The longest time patients with PD spend without any pharma-
cological intervention is at night. This is to avoid the stimulating
effect of dopaminergic therapy, whichmay result in impaired sleep.
However, the long period without any drug treatment can result in
nocturnal “off” periods, the resultant akinesia leading to difﬁculty
turning in bed, stiffness, early morning dystonia, and tremor. There
may also be an increase in NMSs of pain and muscle cramps that
Table 1
Causes of night-time problems in Parkinson disease.
Motor function related Akinesia (difﬁculty turning)
Restless legs syndrome
Periodic limb movements of sleep
Treatment-related motor
function
Nocturnal “off’-period-related tremor
Dystonia
Dyskinesia
“Off”-period-related pain
Paraesthesia
Muscle cramps
Neuropsychiatric/
parasomnias
Depression
Anxiety (generalized, panic attacks, social
phobia)
“Off’-period-related panic attacks
Apathy
Cognitive dysfunction
Vivid dreams
Altered dream content
Nightmares
Night terrors
Sleep talking
Nocturnal vocalizations
Somnambulism
Hallucinations
Sleep dysfunction Insomnia (sleep-onset, sleep-maintenance)
Rapid eye movement sleep behavior disorder
Nonerapid-eye-movement-related sleep
disorders
Akathisia
Autonomic “Off”-period-related incontinence of urine
Nocturia
Nocturia with secondary postural hypotension
Medications
Adapted from Chaudhuri KR. Nocturnal symptom complex in PD and its manage-
ment. Neurology 2003;61(Suppl 3):S17eS23.
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mented due to night-time “off” dyskinesias and akathisia (restless
legs).
Treating these nocturnal “off” symptoms has to be balanced
against the alerting/arousal effects of dopaminergic therapy which
might generate insomnia, vivid dreams, and “on” dyskinesias.
4.2. Neuropsychiatric disorders
Depression affects around 40% of patients with PD.37 The
symptom complex of depression in PD may be hard to distinguishTable 2
NoneParkinson disease-related causes of night-time problems in the elderly.
Age-related sleep
changes
Altered sleep architecture
Altered circadian rhythm
Medical or health
problems
Sleep apnea
Periodic limb movements of sleep
Pain (chronic arthritis)
Heart failure
Palpitations
Frequency of micturition
Gastroesophageal reﬂux disease
Constipation
Allergies
Mental disorders, e.g. depression, anxiety
Dementia (increases nonerapid eye movement light sleep
and decreases in nonerapid eye movement deep sleep)
Medications Beta-blockers
Sleeping medications (e.g. benzodiazepines)
Sedative antidepressants and antipsychotics
Theophylline and caffeine
Other factors Nicotine, alcohol
Sedentary behavior
Daytime napping
Sadness or bereavement/stressfrom early cognitive impairment22; it is linked to dysfunction of
dopaminergic, serotoninergic, and norepinephrinergic pathways in
the limbic system.38 Depression is independently associated with
sleep disorders (e.g., early morning wakening) and can also exac-
erbate motor and drug-related symptoms.
Anxiety disorders often coexist with depression and motor
ﬂuctuations and are usually the result of neurobiological or
neuropeptide abnormalities associated with PD.20 These may
manifest as generalized anxiety states, panic attacks, and social
phobia. If related to a dopamine-dependent “wearing off” state,
anxiety can respond to treatment of the motor dysfunction with
dopaminergic therapy.39 Some anxiety states are independent of
the dopaminergic state these are usually more difﬁcult to treat but
may respond to anxiolytics or antidepressants.
Apathy is a speciﬁc symptom of PD, occurring with or without
depression, for which a dopaminergic basis is possible. The Geri-
atric Depression Scale can help distinguish true depressive symp-
toms from those of apathy.40,41 Apathy is generally associated with
EDS.
Cognitive dysfunction is usually a feature of advanced PD, but
can occur early as a frontal dysexecutive syndrome, manifesting as
impaired adaptive response against competing alternatives.42
Visuospatial and visuoperceptual deﬁcits have also been noted in
patients with PD.43 Mild cognitive impairment (MCI) has been
identiﬁed in 72/126 (56%) of patients with early PD.44 The caudate
and corticostriatal pathways are implicated in early cognitive
changes.45 Brain metabolism and dopamine uptake is impaired in
cortical targets of striatal dopaminergic targets.46,47 Sleep distur-
bances related to cognitive impairment include EDS, nocturnal
hallucinations, and altered dream content.
4.3. Sleep dysfunction
Sleep architecture studies in PD reveal reduced total sleep time
and sleep efﬁciency, sleep arousals and fragmentation, while
circadian variation of symptoms are also reported enabling classi-
ﬁcation into the “morning better,” “morning worse,” and a non-
affected group.36,48
REMSBD is a parasomnia with a population prevalence of
0.5%.49,50 REMSBD causes loss of the normal skeletal muscle atonia
during REM sleep. This enables patients to enact their dreams,
which can be unpleasant or vivid. Spouses and partners report
vocalizations (talking, shouting and vocal threats) and abnormal
movements (limb jerks, falling out of bed, and violent assaults).
This may result in injury to the individual or their sleep partner.
REMSBD disturbs the sleep of patient and partner, impacts on QoL
for patient and partner, often results in poor quality sleep, so there
is EDS, and it can endanger the sleep partner.51
The diagnosis can usually be made from the clinical history but
may sometimes require polysomnography with video telemetry for
conﬁrmation. A total of 11 out of 33 consecutive patients with PD
were diagnosed as having REMSBD by a combination of structured
clinical interview and polysomnography; clinical interview alone
would not have identiﬁed half of these patients.51,52 REMSBD may
predate the diagnosis of PD and represent a preclinical stage: 11 of
29 men aged  50 years developed a Parkinsonian disorder
3.71.4 (standard deviation) years after the diagnosis of REMSBD
and 12.7 7.3 years after the onset of REMSBD.53 REMSBD seems to
be associated with degeneration of lower brainstem nuclei, such as
the pedunculopontine nucleus and locus coeruleus which have
connections with the dopaminergic ventral tegmental area in the
midbrain. These observations are consistent with the Braak
hypothesis27 that the preclinical Stages 1 and 2 of PD start in the
olfactory and medullary area of the brainstem and progress
rostrally. Individuals with olfactory disturbances and REMSBD have
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diagnosis of REMSBD in patients without parkinsonism, Postuma
and colleagues reported the estimated 5-year risk of developing PD
after being diagnosed with REMSBD is 17.7% and the 10-year risk
40.6%.55 REMSBD may also be associated with other nonmotor
manifestations of PD, e.g., hallucinations, orthostatic hypotension,
and dementia.56
Insomnia is probably the most common sleep disturbance in
patients with PD.57 It is often multifactorial and may be related to
motor, NMSs, depression, anxiety, obstructive sleep apnea, urinary
problems, or any combination of these. Sleep-onset insomnia
(difﬁculty in falling asleep) is usually associated with PD itself, but
can occasionally be brought on by dopaminergic therapy, e.g.,
selegiline may delay onset of sleep as a result of its amphetamine
metabolites. Amantadine and anticholinergics may produce an
alerting effect and selective serotonin reuptake inhibitors (SSRIs)
need to be avoided at bedtime given that they may impair sleep
onset.48 Sleep-maintenance insomnia (difﬁculty in maintaining
sleep for periods of time) is usually a result of akinesia and other
“off”-state related motor and NMSs, e.g., RLS, periodic limb move-
ments of sleep (PLMS), nocturia, and reversal of sleep patterns.5,58
RLS is an urge to move the legs, to relieve unpleasant or
uncomfortable sensations brought about by rest, which tends to
worsen in the evening.59 It is associated with insomnia, anxiety,
and depression.60 RLS has a two-fold increase in prevalence in PD
compared with the general population (although the diagnostic
criteria for RLS have not been validated in PD)61 and along with
PLMS (repetitive, rhythmic jerking movements of the limbs during
sleep) is known to cause frequent sleep disruption.62,63 In advanced
PD of the akinetic rigid phenotype, akathisia is common (and
symptoms are similar to those of RLS) probably related to changes
in the mesocortical dopamine pathways.64 PD often precedes RLS
suggesting RLS may be a secondary phenomenon. RLS may be
associated with iron deﬁciency and in such cases will respond to
iron replacement therapy. RLS may also be associated with renal
impairment.
EDS describes a tendency to fall asleep in the daytime, which
may interfere with social functioning, cognition and contribute to
accidents and falls.65,66 Care must be taken to differentiate EDS
from symptoms of chronic fatigue that also occur in PD. EDS can
occur in the early stages of PD67 and may even predate the diag-
nosis of PD.68 EDS has a higher prevalence in patients with PD than
in controls (affecting approximately 50% of patients with PD), does
not appear to be age-related, and is more severe in the later
stages of PD.69,70 Thus, EDS may be related to the underlying
neurodegeneration.
The manifestations of EDS are profoundly variable; some feel
sleepy and slowly drift off to sleep, while others have rapid-onset
sleep without any preceding drowsiness resembling narcolepsy.31
There is evidence of a correlation between EDS and the use of
dopamine agonists, but not with levodopa.65,71e73 So-called “sleep
attacks” (falling asleep without a prodrome) are rare and may be
associated with dopamine agonist usage.
In most instances EDS will be multi-factorial due to a combina-
tion of sleep fragmentation, depression, coexistent sleep apnea, and
the use of hypnotics, antidepressants, and DAs.
4.4. Nocturia
Nocturia is a common problem in older age. However, symp-
toms of overactive bladder syndrome are more common in patients
with PD than age-matched controls and these symptoms worsen as
PD progresses.18,74,75 Both the presence and severity of urinary
symptoms appear to correlate with the extent of dopaminergic
neurone depletion.76The high incidence of nocturia in patients with PD is likely due
to a combination of reduced bladder capacity, increased urine
formation at night, impairment of sleep due to “off” period,
urgency, and detrusor overactivity.
4.5. Obstructive sleep apnea
Snoring and obstructive sleep apnea (OSA) are three times more
common in patients with PD as controls andmay occur in up to 50%
of patients with PD.77 OSA may also occur in conjunction with RLS,
PLMS, or REMSBD.67,69 Patients with PD with OSA typically have
a normal body mass index unlike patients without PD but with
OSA.69
Reduced neural output causes relative weakness of the muscles
around the upper airway leading to partial or complete airways
collapse. The resultant hypoxia promotes sufﬁcient awakening to
stimulate breathing. Thesemicroawakenings leave the individual in
a state of light sleep, which is nonrestful, so he or she is fatigued
and somnolent during the day. His or her sleep partner may be
aware of the patient’s loud snoring, periods of apnea, and gasping.
Correct diagnosis is essential for these patients to have speciﬁc and
targeted treatment.
OSA can be diagnosed by overnight oxygen saturation moni-
toring and polysomnography.78 It can be treated by overnight
continuous positive airway pressure (CPAP).
4.6. Other causes
It is all too easy to ascribe every symptom to the PD. A thorough
search should also be made for nonePD related causes of nocturnal
disturbances in patients with PD, e.g., other medical ailments and
adverse events of medications.
5. Assessment of sleep disturbance
Given the varied nocturnal symptoms in patients with PD, the
ﬁrst step toward management is identiﬁcation of such problems by
qualitative and quantitative means. Speciﬁc questioning of patient
and sleep partner should include:
 Sleep pattern, including insomnia, EDS, and “sleep attacks”
 RLS
 Vivid dreams and hallucinations
 Acting out dreams (REMSBD)
 Nocturnal motor symptoms (including PLMS)
 Nocturia and other urinary symptoms
 Medication (PD and nonePD)
 Comorbidities
 Snoring and apneic attacks
The gold standard for quantiﬁcation of sleep disorders is poly-
somnography and sleep latency tests; however, these are costly and
often of limited availability.
5.1. Scales and measures
Sleep dysfunction can be assessed (presence and severity) by
several scales, of which six are recommended by the Movement
Disorder Society (MDS).79 This is shown in Table 3. These are all
screening tools that cannot diagnose speciﬁc sleep disturbances in
PD but can assess severity and response to treatment.
The Parkinson’s Disease Sleep Scale (PDSS) is a 15-question
visual analogue scale that can be used at the bedside and is avail-
able in ﬁve languages (English, German, Italian, Swedish, and
Spanish).80 It has robust testeretest reliability and good
Table 4
Good sleep hygiene.
Avoid daytime napping
Increase daytime exercise
Avoid alcohol, caffeine, and tobacco
Avoid heavy meals or excessive liquid late in the day
Go to bed only when sleepy
Go to bed to sleep, not to read or watch television
Try to maintain a regular sleep pattern
If unable to sleep, get up and engage in relaxing activity, i.e., reading a book, and
then return to bed when drowsy
Table 3
Sleep scales in Parkinson disease.
Scale Number of
items to
complete
Assessment details
Parkinson’s Disease Sleep
Scale
15 Nocturnal disturbance and
excessive daytime somnolence
Time scale: Over previous weeks
Pittsburgh Sleep Quality
Index
19 Sleep quality
Time scale: Over the previous month
Scales for Outcomes in
Parkinson’s Disease
Sleep Scale
12 Sleep quality, daytime sleepiness
and night-time sleep disturbances
Time scale: Over the previous month
Epworth Sleepiness Scale 8 Daytime sleepiness presence and
severity
Time scale: In recent times
Inappropriate Sleep
Composite Score
6 Risk of sudden onset of sleepiness
while driving
Stanford Sleepiness Scale 1 General level of daytime
sleepiness
Time scale: At that speciﬁc moment
in time
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individuals.58 The PDSS has recently been revised and validated
(PDSS-2) to include an extended spectrum of nocturnal distur-
bances, and may better reﬂect response to treatment.81 The 12-
item Scales for Outcomes in Parkinson's disease-Sleep (SCOPA-
SLEEP) scale assesses both night-time and daytime sleep; though
validated, it does not address some of the night-time symptoms of
PD very well.82 The Epworth Sleepiness Scale (ESS) is very speciﬁc
for assessing EDS in eight daily situations but lacks testeretest
reliability and cross-cultural differences.83
Depression may be assessed by a variety of scales, such as the
Geriatric Depression Scale (GDS), Montgomery-Asberg Depression
Rating Scale (MADRS), and the Zung self-rating depression scale.
Anxiety may be assessed using the State Trait Anxiety Inventory
and the Hospital Anxiety and Depression (HAD) scale.
Objective measurements of sleep in PD patients include poly-
somnography (PSG), multiple sleep latency tests (MSLT) and
maintenance of wakefulness test (MWT). PSG includes objective
assessment of the entire gamut of standardized measurements of
brain activity, respiratory functions, eye movements, and electro-
myography (EMG) to measure sleep architecture and provide
quantitative measurements of sleep disturbance, which are useful
for diagnosing sleep apnea, PLMS, and REMSBD. The MSLT and
MWT are useful for evaluation of EDS and the ability to remain
awake.
5.2. Evaluation of nocturnal sleep disorders
Clues to the presence of nocturnal sleep disturbances may be
obtained by interviewing the bed partner. Snoring and respiratory
pauses would suggest OSA, whereas kicking during the night would
point to PLMS and dream enactment behaviors suggest REMSBD.
However, the differentiation of these conditions is not always clear-
cut as there is considerable overlap in symptomatology. PSG is
essential for diagnosis of PLMS, which is an intermittent, rhythmic
movement of the legs mainly occurring in noneREM sleep.
Although PSG is the gold standard, thorough interviews of the
patient and their sleep partner are invaluable bedside tools.
5.3. Evaluation of EDS
It is generally assumed that EDS worsens nocturnal symptoms
and vice versa. However, EDS can occur without signiﬁcantnocturnal problems.48 A good pointer for EDS is an elevated ESS
score, which predicts the occurrence of sleepiness and dozingwhile
driving.84 Subjective reports of EDS underestimate those diagnosed
by MSLT.85
6. Treatment options
The approach to managing sleep disturbances in patients with
PD (especially in the older population) requires a holistic view,74
bearing in mind that some of the symptoms may arise from the
interplay of other comorbidities. Well being of the sleep partners or
carers is also important in formulating a treatment plan. Ensuring
good sleep hygiene is a key element to managing all sleep distur-
bances (Table 4).86
Bed rails and straps can help make turning in bed easier as can
silk sheets. Spouses of patients with REMSBD may need to move in
to a separate bed or bedroom as may those of patients with severe
snoring.
Treatment should be targeted at the causal factors disrupting
sleep, whether PD or comorbidity related and may consist of non-
pharmacological as well pharmacological strategies (Table 5).
However, the patient should be warned that full resolution of
symptoms is unlikely and that a strategy to improve one symptom
may worsen another.
6.1. Nocturnal sleep disturbances
6.1.1. Sleep fragmentation and insomnia due to symptoms of PD
Some nonpharmacological strategies include:
 Having a hot bath before bedtime, which may shorten sleep-
onset time by inducing sleep during the cooling phase
 Light bedtime snacks may alleviate symptoms of night-time
hunger
 Avoiding ﬂuid intake in the evening may reduce nocturia
 Relaxation techniques may help reduce stress and muscle
tension
Subtle changes in PD medication regimens may result in major
beneﬁts in nocturnal sleep quality and subsequent daytime alert-
ness. Strategies to improve nocturnal motor symptomsmayworsen
insomnia or induce vivid dreams. There often needs to be a degree
of trial and error, and patients should be counselled regarding this.
Targeting the individual’s most troublesome symptoms is most
likely to result in the best improvements in QoL.
Bedtime dosing of sustained-release levodopa preparations can
help in reducing early morning PD symptoms, e.g., dystonia87 and
the addition of a catechol-O-methyltransferase inhibitor (COMT-I),
such as entacapone or tolcapone, to the bedtime dose of levodopa
can prolong its effect.88 Alternatively, a nocturnal (on wakening)
use of standard formulation or sustained-release levodopa may be
helpful.
Table 5
Potential pharmacologic treatments for sleep disturbances in Parkinson disease.
Symptom Pharmacologic treatment
“Off” symptoms Prolonged release levodopa
Rotigotine patch
Dystonia Prolonged release levodopa
Rotigotine patch
Akathisia Clozapine89
Restless legs syndrome Reduce antidepressants
Periodic limb movements
of sleep
Ropinirole
Pramipexole
Iron
Rapid eye movement sleep
behavior disorder
Clonazepam
Melatonin
Insomnia Melatonin
Quetiapine
Benzodiazepines/zolpidem
Sedating antihistamines
Excessive daytime somnolence Reduce dopaminergic drugs, antihistamines,
and hypnotics
Modaﬁnil
Methylphenidate
Sleep attacks Review non-ergot dopamine agonists
Depression Antidepressants
Overactive bladder Antimuscarinics
Obstructive sleep apnea Review sedative medication
Continuous positive airways pressure
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a DA. In the RECOVER trial, transdermal rotigotine showed statistical
improvement in almost all domainsof PDSS-2: sleep-onset insomnia,
early morning tiredness, nocturnal restlessness of limbs, early
morning dystonia, earlymorning tremors, limb pain,muscle cramps,
and breathing problems.90 In EASE-PD, addition of prolonged release
ropinirole to levodopa improved sleep as evidenced by change in
baseline PDSS score.91 A post-hoc subgroup analysis of EASE-PD
showed improvements in early morning motor symptoms and
global quality of sleep in those with PDSS scores  100 and in global
quality of sleep for those with PDSS scores> 100.92 The subgroup of
PDSSwith scores100have troublesomenocturnal symptoms in the
form of greater daily awake ‘off’ time, reduced night-time sleep, and
worseQoL comparedwith thosewithPDSS scores> 100. The CLinical
Efﬁcacy Of Pramipexole And Transdermal Rotigotine in Advanced
Parkinson's Disease (CLEOPATRA-PD) study showed equal beneﬁt of
pramipexole or transdermal rotigotine over placebo.93
The hypnosedative zolpidem may be useful both for its sedative
(insomnia) and muscle relaxing effects (insomnia and motor
problems of PD).94
Melatonin (3 mg at night) has been shown to improve subjec-
tive sleep quality in a number of PD patients although there was no
change in objective measures using PSG.95
Deep brain stimulation (DBS) of the subthalamic nuclei (STN)
helps improve motor symptoms and sleep architecture (increased
total sleep time and improved sleep maintenance) in PD,96 but
would not be recommended purely for this purpose.
6.1.2. Sleep fragmentation due to obstructive sleep apnea
Although CPAP is the most effective treatment for OSA, there are
no data speciﬁc for its use in patients with PD.
6.1.3. Sleep fragmentation due to RLS and PLMS
Some nonpharmacological measures include:
 Good sleep hygiene
 Avoidance of alcohol, tobacco and caffeine
 Avoidance of drugs that exacerbate RLS: serotonergic and
tricyclic antidepressants, antihistamines, and dopamine-
receptor antagonists Correction of iron deﬁciency: iron replacement has been
effective in reduction of RLS symptoms in non-Parkinsonian
patients97 and, hence, should be considered if ferritin levels
are low. Although controlled trials are lacking, oral iron as
ferrous sulphate concomitantly with vitamin C for absorption
of food may be tried.98 The cause of iron deﬁciency will need to
be ascertained
The drug of choice for RLS and PLMS is a DA (pramipexole,
ropinirole, or rotigotine).99 When a DA cannot be used, e.g., the
cognitively impaired or produces untoward effects, e.g., orthostatic
hypotension, then alternatives include opiates, anticonvulsants
(gabapentin), and benzodiazepines.100
6.1.4. REMSBD
Where REMSBDmanifests as aggressive and/or violent behavior,
environmental adjustment should be considered to protect the
patient and his or her bed partner,98 e.g., padding the ﬂoor, using
raised padded bed rails, and sleeping in different rooms.
Low-dose clonazepam (0.5e1.0 mg), at night has been reported
to improve REMSBD in 80%e90% patients101 but controlled trials
are lacking. Higher doses of clonazepammay run the risk of adverse
effects of nocturnal confusion, daytime sleepiness, and worsening
of OSA (if present).
Melatonin may improve REMSBD in doses up to 12 mg at
night102; adverse effects include morning headaches, morning
drowsiness, and delusions or hallucinations. Symptomatic
improvement of REMSBD in PD patients has also been reported
with pramipexole.103 A small case series reported improvement of
REMSBD with donepezil.104
6.1.5. Depression
Depression and anxiety may respond to improvements in motor
symptoms due to adjustments in dopaminergic therapy. Prami-
pexole has also been shown to be of similar antidepressant activity
as ﬂuoxetine105 better than sertraline106 in improving mood when
used as an adjunct to levodopa. This may be a class effect of DAs at
the limbic dopamine D3 receptors, as both pramipexole and per-
golide showed comparable beneﬁts in MADRS scores.107 In the
EASE-PD Adjunct Study, prolonged-release ropinirole also
improved mood as assessed by the Beck Depression Inventory.91
The evidence base for choosing an antidepressant in PD is poor
and so no particular antidepressant can be recommended over
another.108,109 However, it is perhaps worth noting that bupropion
and sertraline appear to inhibit dopamine reuptake21,110 and so,
theoretically may beneﬁt motor symptoms as well as mood.
6.1.6. Nocturnal hallucinations/vivid dreams
Symptomatic improvement may be achieved by reduction (or
removal) of evening doses of antiparkinsonian medications. Occa-
sionally, atypical neuroleptics may be necessary; adverse events
may be avoided by starting at low doses and gradually titrating up
to the effective dose for that individual. Clozapine has been shown
to reduce psychosis, anxiety, and hypersexuality in patients with
PD.111 However, use is limited by a need to regularly monitor blood
count and prescribing being limited (in many parts of the United
Kingdom) to consultant psychiatrists. Quetiapine is the drug of
choice in clinical practice at a starting dose of 12.5e25 mg.
6.1.7. Nocturia
Some nonpharmacological measures to reduce nocturia include:
 Good sleep hygiene
 Avoidance of caffeine, alcohol
 Bladder training: voiding of urine before sleeping
S. Roychowdhury, D.R. Forsyth / Journal of Clinical Gerontology & Geriatrics 3 (2012) 53e61 59 Reduction of ﬂuid intake beyond the evening
 Bedside commode, pads, or conveen sheath urinal
Overactive bladder syndrome may beneﬁt from drugs with
antimuscarinic properties, such as tolterodine, oxybutynin, and
solifenacin, but these drugs have the potential to cause or worsen
confusion. If nonpharmacological and pharmacological measures
fail, then botulinum toxin may be beneﬁcial.112
Prostatism is a common comorbidity and may indicate a need
for urodynamic studies if obstructive symptoms are signiﬁcant.
6.2. EDS
Some nonpharmacological measures to reduce EDS include:
 Good sleep hygiene
 Avoiding sedentary activities and participating in external
activities (day centers) may provide stimulation
 Avoid driving due to increased risk of vehicle accidents during
periods of “sleep attacks”
 Physical exercise appropriate to level of functioning may help
increase daytimewakefulness; avoidance of strenuous exercise
for 3e4 hours prior to sleep
It may be necessary to reduce the dose or stop using DAs
completely.85 EDSmayworsenwith all dopaminergic therapy but is
more marked with DAs than levodopa. In more severe cases of EDS,
e.g., where the individual is falling asleep during meals or mid-
conversation, then the stimulant modaﬁnil may be of beneﬁt,
although the trial evidence is conﬂicting.113,114 Methylphenidate
may be worth trying, when all other options fail.115 Caffeine (an
adenosine A2A receptor antagonist) may be a more affordable
alternative, albeit with no evidence base for its use in EDS.
7. Conclusion
Sleep disturbances are common in patients with PD and their
sleep partners, but they are often overlooked by an emphasis on the
motor manifestations of PD. The presence and cause(s) of sleep
disturbances need to be identiﬁed as appropriate management can
signiﬁcantly improve the QoL of the person with PD and his or her
caregiver. A number of assessment tools have been developed to aid
in the detection and management of sleep problems in patients
with PD.
It is imperative upon all healthcare professionals dealing with
patients with PD to update them and gain experience in the diag-
nosis and management of these conditions. Although the evidence
base is weak, all patients with PD will potentially beneﬁt from
advice on good sleep hygiene, while more speciﬁc pharmacological
therapies will need to be tailored to each individual’s sleep prob-
lem(s). Patients and caregivers should be warned of the potential
limitations of therapeutic interventions and treatment should be
targeted at their most troublesome symptoms.
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